Can a Two-Drug combo outsmart returning childhood cancers?

NCT ID NCT00918320

First seen Aug 19, 2026 · Last updated Aug 19, 2026

Summary

This phase 2 trial is testing whether combining two chemotherapy drugs—temozolomide and topotecan—can help children with neuroblastoma, brain tumors, or other solid tumors that have come back or not responded to standard treatment. Participants receive temozolomide by mouth and topotecan by IV once daily for five days per cycle. The main goal is to see how often tumors shrink or disappear, while also tracking side effects and how long any benefit lasts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
A combination of two chemotherapy drugs: temozolomide (taken by mouth) and topotecan (given by IV infusion).
What this could lead to
If effective, this drug combination could offer a new treatment option for children with hard-to-treat or returning solid tumors, potentially slowing disease or shrinking tumors.
What could go wrong
This is an early-phase trial, so the combination may not work for all tumor types. Chemotherapy also carries risks like low blood counts, fatigue, and increased infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Institut Gustave Roussy

    Villejuif, 94805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.